RxDoctor Payments Data

Anton Koopman, MD

Family Medicine · Columbus, INNPI 1538182035

Payments from drug & device makers

$4,486in general payments, 2019–2025

Across 249 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$401
  • Lilly USA, LLC$398
  • GSK$384
  • AbbVie$301
  • Otsuka America Pharmaceutical, Inc.$164
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,37998%
  • Education$110%
  • Gifts$962%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,486 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$132,796
Medicare patients
207
Services billed
2,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$114,400
MounjaroTirzepatide82$109,839
JardianceEmpagliflozin34$46,446
FarxigaDapagliflozin Propanediol32$39,918
VraylarCariprazine Hcl13$33,159
EliquisApixaban19$26,217
JanuviaSitagliptin Phosphate23$25,521
LinzessLinaclotide18$24,955
TrulicityDulaglutide21$20,764
XareltoRivaroxaban12$19,657
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$18,360
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,576
Celecoxib213$10,246
Breo ElliptaFluticasone/Vilanterol20$9,521
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen252$9,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$384$134,497171 claims
Lilly USA, LLCMounjaro, Trulicity$398$130,604103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,316$62,28164 claims
AbbVieVraylar, Linzess$301$58,11431 claims
Boehringer IngelheimJardiance$86$46,44634 claims
PfizerEliquis$55$26,21719 claims
MerckJanuvia$23$25,52123 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,666184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →